Susquehanna International Group’s Bicycle Therapeutics BCYC Stock Holding History

Susquehanna International Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$75.6K	Buy	+16,300	New	+$93.2K	﹤0.01%	12480
2025 Q4	–	Sell	-21,100	Closed	-$163K	–	12350
2025 Q3	$163K	Buy	+21,100	New	+$159K	﹤0.01%	11200
2024 Q2	–	Sell	-9,100	Closed	-$227K	–	12043
2024 Q1	$227K	Sell	9,100 -17,900	-66%	-$380K	﹤0.01%	10339
2023 Q4	$488K	Buy	+27,000	New	+$447K	﹤0.01%	8724
2023 Q2	–	Sell	-18,100	Closed	-$385K	–	12059
2023 Q1	$385K	Buy	18,100 +7,500	+71%	+$188K	﹤0.01%	9178
2022 Q4	$314K	Buy	+10,600	New	+$284K	﹤0.01%	8987
2022 Q3	–	Sell	-18,300	Closed	-$307K	–	13154
2022 Q2	$307K	Sell	18,300 -75,900	-81%	-$1.6M	﹤0.01%	9509
2022 Q1	$4.13M	Buy	94,200 +66,000	+234%	+$3.08M	﹤0.01%	3984
2021 Q4	$1.72M	Buy	28,200 +19,300	+217%	+$1.06M	﹤0.01%	5872
2021 Q3	$370K	Buy	+8,900	New	+$311K	﹤0.01%	10100

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's BCYC Position: Q1 2026 in Review

Susquehanna International Group reduced its Bicycle Therapeutics (BCYC) stake by 65% in Q1 2026, selling an estimated $403K and leaving 37,888 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #11829.

Susquehanna International Group first reported a position in BCYC in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.6M in Q2 2023. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Susquehanna International Group held 37,888 shares of Bicycle Therapeutics worth $176K as of Q1 2026.
Susquehanna International Group sold 70,535 Bicycle Therapeutics shares in Q1 2026, an estimated $403K.
Bicycle Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11829 holding.
Susquehanna International Group first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 10 quarters since.
Susquehanna International Group's Bicycle Therapeutics position peaked at $1.6M in Q2 2023.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.